Cargando…

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6 i), abemaciclib, palbociclib, and ribociclib, have been FDA-approved for the treatment of hormone receptor-positive (HR+), HER2−negative (HER2−) advanced breast cancer (aBC). This targeted therapy has revived hope in those aBC patients who d...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Angelo, Alberto, Giudici, Fabiola, Chapman, Robert, Darlow, Jacob, Kilili, Huseyin, Sobhani, Navid, Cinelli, Mattia, Cappelletti, Maria Rosa, Strina, Carla, Milani, Manuela, Generali, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497904/ https://www.ncbi.nlm.nih.gov/pubmed/36135204 http://dx.doi.org/10.3390/cimb44090292

Ejemplares similares

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
por: Schettini, Francesco, et al.
Publicado: (2020)

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
por: Schettini, Francesco, et al.
Publicado: (2021)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses
por: D’Angelo, Alberto, et al.
Publicado: (2023)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2014)

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
por: Sammons, Sarah L., et al.
Publicado: (2017)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
por: Azoz, Seyla, et al.
Publicado: (2023)

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
por: D’Angelo, Alberto, et al.
Publicado: (2020)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020)

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
por: Sobhani, Navid, et al.
Publicado: (2021)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2020)

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study
por: Corona, Silvia P., et al.
Publicado: (2022)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
por: Zhao, Joseph J., et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
por: Zhang, Jian, et al.
Publicado: (2021)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis
por: Chang, Yu-Cheng, et al.
Publicado: (2023)

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2022)

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
por: Bernocchi, Ottavia, et al.
Publicado: (2021)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
por: Elfgen, Constanze, et al.
Publicado: (2021)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
por: Sobhani, Navid, et al.
Publicado: (2023)

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2014)

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
por: Sobhani, Navid, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ottp5cekvc3i0g7h4mr39klood